Eli Lilly (LLY) USD (CDI)

Sell:$804.89Buy:$804.90$24.08 (2.92%)

Prices delayed by at least 15 minutes
Sell:$804.89
Buy:$804.90
Change:$24.08 (2.92%)
Deal now
Prices delayed by at least 15 minutes
Sell:$804.89
Buy:$804.90
Change:$24.08 (2.92%)
Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

Eli Lilly and Company is a medicine company, which discovers, develops, manufactures and markets products in the human pharmaceutical products segment. Its cardiometabolic health products include Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; and Zepbound. Its oncology products include Cyramza, Erbitux, Tyvyt, and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. The Company, through its subsidiary, POINT Biopharma Global Inc., is engaged in radiopharmaceutical discovery, development, and manufacturing efforts, as well as clinical and pre-clinical radioligand therapies in development for the treatment of cancer. It is also developing an oral small molecule inhibitor of α4β7 integrin for inflammatory bowel disease (IBD). It also owns a lead therapeutic molecule FXR314.

Key people

David A. Ricks
Chairman of the Board, President, Chief Executive Officer
Lucas E. Montarce
Chief Financial Officer, Executive Vice President
Diogo Rau
Executive Vice President, Chief Information and Digital Officer
Daniel M. Skovronsky
Executive Vice President, Chief Scientific Officer and President - Lilly Research Laboratories and Lilly Immunology
Anat Hakim
Executive Vice President, General Counsel, Secretary
Eric Dozier
Executive Vice President - Human Resources and Diversity
Edgardo Hernandez
Executive Vice President, President - Manufacturing Operations
Patrik Jonsson
Executive Vice President, President of Lilly Cardiometabolic Health and President, Lilly USA
Melissa Seymour
Executive Vice President - Global Quality
Jacob S. Van Naarden
Executive Vice President, President - Lilly Oncology
Juan Ricardo Luciano
Lead Independent Director
Raul Alvarez
Independent Director
Katherine Baicker
Independent Director
J. Erik Fyrwald
Independent Director
Mary Lynne Hedley
Independent Director
Click to see more

Key facts

  • EPIC
    LLY
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US5324571083
  • Market cap
    $779.73bn
  • Employees
    47,000
  • Shares in issue
    948.35m
  • Exchange
    New York Stock Exchange
  • Index
    S&P 500, TR Equity United States Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.